EP14.05-009 LUMINANCE: A Phase IIIb Study of Durvalumab + Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)

Abstract

Immune checkpoint inhibitors combined with chemotherapy have become standard-of-care first-line treatment for ES-SCLC in recent years. In the phase III CASPIAN study, the PD-L1 inhibitor durvalumab, in combination with platinum-etoposide (EP), demonstrated a statistically significant improvement in overall survival (OS) vs EP alone in first-line treatment of ES-SCLC (HR 0.73 [95% CI 0.59-0.91; p=0.0047]); OS benefit was sustained after >3 years median follow-up (HR 0.71 [95% CI 0.60‒0.86; nominal p=0.0003]).